Literature DB >> 32238232

[From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment].

X Wang1, Y Q Ding2.   

Abstract

COVID-19 is an infectious disease caused by 2019-nCoV and characterizes as an atypical pneumonia. Since 2019-nCoV is a newly emerging virus, the pathogenesis of COVID-19 is not well known. Most patients had a self-limited course, and some became severe even death. In this review, the authors compared two coronavirus outbreaks during the past two decades: the SARS-CoV and 2019-nCoV. Among the biological nature of the pathogens, viral receptor distribution on the human cells, and the pathological findings in the targeted organs and clinical features of the patients with the diseases, found similarities and differences between the two diseases had been found. Due to the shared receptor ACE2 and the pathological similarities of the SARS-CoV and 2019-nCoV diseases,authors proposed a pathogenesis model for COVID-19. Like the SARS-CoV disease, COVID-19 is a systematic disease and targets the lungs, vasculatures, and the immune system. The basic pathogenesis involves two interlinked processes: a severe lung inflammation and immune deficiency, both of which were related to an inappropriate immune response and over-production of cytokines. Thus, treatment approaches should include antiviral and anti-proinflammatory cytokines, anti-infectious and life support therapies, especially in patients with severe diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32238232     DOI: 10.3760/cma.j.cn112151-20200318-00220

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  7 in total

Review 1.  Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review.

Authors:  Christodoulos Papadopoulos; Dimitrios Patoulias; Eleftherios Teperikidis; Dimitrios Mouselimis; Anastasios Tsarouchas; Maria Toumpourleka; Aristi Boulmpou; Constantinos Bakogiannis; Michael Doumas; Vassilios P Vassilikos
Journal:  SN Compr Clin Med       Date:  2020-08-04

2.  Treatment efficacy of Lianhua Qingwen capsules for eraly-stage COVID-19.

Authors:  Si-Jia Fan; Jian-Kun Liao; Liu Wei; Bai-Yu Wang; Liu Kai; Du-Xun Tan
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

3.  Hypercytokinemia and Pathogen-Host Interaction in COVID-19.

Authors:  Alaa Badawi
Journal:  J Inflamm Res       Date:  2020-06-23

4.  The receptor for advanced glycation end product (RAGE) pathway in COVID-19.

Authors:  Demet Yalcin Kehribar; Mustafa Cihangiroglu; Emine Sehmen; Bahattin Avci; Aylin Capraz; Ayse Yildirim Bilgin; Caner Gunaydin; Metin Ozgen
Journal:  Biomarkers       Date:  2021-01-13       Impact factor: 2.658

Review 5.  Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review.

Authors:  Xiao-Bin Zhu; Meng Guo; Zhi-Hui Zhang; Li-Hua Sun; Lei Liu; Li-Juan Zhou; Chun-Lei Shan; Yi Yang; Lian-Di Kan; Liu-Cheng Li
Journal:  Integr Med Res       Date:  2021-09-30

Review 6.  Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects.

Authors:  Liu-Cheng Li; Zhi-Hui Zhang; Wen-Cheng Zhou; Jie Chen; Hua-Qian Jin; Hong-Mei Fang; Qin Chen; Ye-Cheng Jin; Jiao Qu; Lian-Di Kan
Journal:  Biomed Pharmacother       Date:  2020-08-19       Impact factor: 6.529

Review 7.  Intracerebral hemorrhage in COVID-19: A narrative review.

Authors:  Nikolaos Panagiotis Margos; Andreas Stylianos Meintanopoulos; Dimitrios Filioglou; John Ellul
Journal:  J Clin Neurosci       Date:  2021-05-04       Impact factor: 2.116

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.